Philadelphia Drug Discovery Forum

Jason DeHart, Ph.D., Dispatch Biotherapeutics

"A Universal Approach to Solid Tumors Using Tumor-Specific Virus and CAR T Combination Therapy"

Jason Lamontagne, Ph.D., GEMMA Biotherapeutics

"A Disease-Agnostic, Platform-Based Gene Editing Approach to Treat Rare Monogenic Diseases"

Doors open at 3:30 p.m. Program begins promptly at 4 p.m. Reception follows from 5 to 6 p.m.